ACTI.ST

Active Biotech AB (publ) [ACTI.ST] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ACTI.ST Stock Summary

Top 10 Correlated ETFs

ACTI.ST

Top 10 Correlated Stocks

ACTI.ST

In the News

ACTI.ST Financial details

Company Rating
-
Market Cap
220.23M
Income
-45.5M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-2.84
Forward P/E
-
PEG
0.88
P/S
-
P/B
104.02
P/C
-
P/FCF
-4.01
Quick Ratio
0.58
Current Ratio
0.91
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.16
EPS next Y
-
EPS next Q
-
EPS this Y
-26.09%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.14%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
22.01%
-
-
-
-
SMA20
-
SMA50
-10%
SMA100
-64%
Inst Own
-
Inst Trans
-
ROA
-333%
ROE
-270%
ROC
-10.42%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.4005-1.478
52W High
-
52W Low
-
RSI
47.34
Rel Volume
1.49
Avg Volume
2.11M
Volume
3.15M
Perf Week
-16.73%
Perf Month
-0.73%
Perf Quarter
-54.67%
Perf Half Y
-70.86%
-
-
-
-
Beta
0.35
-
-
Volatility
0%, 0.01%
Prev Close
-4.23%
Price
0.0816
Change
-4.45%

Something similar

Top by Market Cap
1YD.DE
APC.DE
GOOG
FXAIX
META
Top Correlated ETFs
JPNE.DE
JPSR.L
JPXX.L
SUJA.L
HSJP.L
Top Correlated Stocks
ALVGO.PA
DXRX.L
BRY.TO
ERCB.DE
LUCE.L
Similar Market Cap
MDG.WA
IUUS.L
ISCG
MWD.TO
CZA

Company Profile

Healthcare Biotechnology
  • Volume Average 2.11M
  • Market Capitalization 220.23M
  • Employee 8
  • CEO Ms. Helen Tuvesson Ph.D.
  • Headquarters Lund,SE
  • IPO Date 2003-12-19
  • Website https://www.activebiotech.com

Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.